This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten H, Graux C et al. Cytarabine dose for acute myeloid leukemia. N Eng J Med 2011; 364: 1027–1036.
Fernandez H, Sun Z, Yao X, Litzow M, Luger S, Paietta E et al. Anthracycline dose intensification in acute myeloid leukemia. N Eng J Med 2009; 361: 1249.
Bradstock K, Matthews J, Lowenthal R, Baxter H, Catalano J, Brighton T et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005; 105: 481–488.
Bishop J, Matthews J, Young G, Szer J, Gillett A, Joshua D et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996; 87: 1710.
Mandelli F, Vignetti M, Suciu S, Stasi R, Petti M-C, Meloni G et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 2009; 27: 5397–5403.
Buchner T, Berdel W, Schoch C, Haferlach T, Serve H, Kienast J et al. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 2006; 24: 2480.
Weick J, Kopecky K, Appelbaum F, Head D, Kingsbury L, Balcerzak S et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996; 88: 2841.
Braess J, Spiekermann K, Staib P, Gruneisen A, Wormann B, Ludwig W et al. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. Blood 2009; 113: 3903.
Wheatley K, Goldstone AH, Littlewood T, Hunter A, Burnett AK . Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party. Br J Haematol 2009; 146: 54–63.
Ventura G, Hester J, Smith T, Keating M . Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol 1988; 27: 34–37.
Thiebaut A, Thomas X, Belhabri A, Anglaret B, Archimbaud E . Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol 2000; 79: 501–506.
Smith G, Damon L, Rugo H, Ries C, Linker C . High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 1997; 15: 833–839.
Acknowledgements
We thank the Australasian Leukemia and Lymphoma Group and the Centre for Biostatistics and Clinical Trials for compiling clinical data and ALLG physicians for recruiting patients to the ALLG M7 study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
van der Jagt, A., Muirhead, J., Seymour, J. et al. Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML. Leukemia 26, 362–365 (2012). https://doi.org/10.1038/leu.2011.201
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.201